Intelligent Diagnosis of Bladder Cancer Staging and Prediction of New Adjuvant Chemotherapy Efficacy Based on Deep Learning and Transfer Learning in Ultrasound-Magnetic Resonance-Pathology Multimodal Multiscale

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

Bladder cancer is the most common malignant tumor of the urinary system. The presence or absence of muscle invasion in early bladder cancer is an independent prognostic factor. The involvement of muscle invasion affects the choice of surgical methods and treatment. Preoperatively, the precise assessment of bladder cancer staging has important practical value. A more accurate preoperative assessment of bladder cancer staging can reduce overtreatment and provide a favorable basis for clinicians to choose more reasonable and effective surgical methods. Clinically, there has been a longstanding desire to diagnose the staging of bladder cancer through a simple, convenient, effective, and non-invasive examination. As relevant research progresses, a multi-omics diagnostic model will be beneficial in improving diagnostic efficiency. This project aims to establish a multi-omics artificial intelligence system based on deep learning and transfer learning to accurately diagnose the staging of bladder cancer and predict the efficacy of neoadjuvant chemotherapy. This system will assist in clinical treatment decision-making.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

• Ultrasound and other imaging examinations (CT, MR, etc.) suggest bladder masses and are suspicious for bladder cancer patients.

• The bladder is well filled, and no allergic reactions to ultrasound contrast agents are found.

• No surgery or radiotherapy/chemotherapy has been performed.

• Patients who meet the indications for surgical resection and are planned for surgical treatment, including one of the following:

‣ Clinical symptoms consistent with suspected bladder cancer (such as gross hematuria, etc.);

⁃ Patients with confirmed primary or recurrent bladder cancer by cystoscopic biopsy;

⁃ Rapid urine cytology and urine cytology FISH testing suggest malignancy.

Locations
Other Locations
China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
RECRUITING
Guangzhou
Contact Information
Primary
Qiyun Ou, Dr.
ouqy5@mail.sysu.edu.cn
(86)020-34071020
Time Frame
Start Date: 2024-01-01
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 480
Treatments
Training Group
Approximately 300 patients, which are used for the training dataset.
Internal Validation Group
Approximately 100 patients, which are used for internal validation to assess the accuracy of the model.
External Validation Group
Approximately 100 patients,which are used for external validation to assess the accuracy of the model.
Related Therapeutic Areas
Sponsors
Leads: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

This content was sourced from clinicaltrials.gov